NCT00116961View on ClinicalTrials.gov

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

December 31, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

Velcade

DRUG

Doxil

DRUG

Dexamethasone

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00116961 - Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | Biotech Hunter | Biotech Hunter